New FDA-Cleared Blood Pressure Monitor from Tenovi Supports Maternal Care and Stroke Prevention
As part of its commitment to preventive, accessible healthcare, Tenovi is launching the new Tenovi cellular-connected blood pressure monitor with irregular heartbeat detection, for use with Tenovi's large-size cuff. It is FDA-cleared for use in maternity care and for adults with diabetes, pregnancy, or preeclampsia.
Stroke is often linked to unmanaged chronic conditions such as hypertension. With 129 million Americans living with chronic illnesses, Tenovi is committed to closing care gaps and making preventive, proactive healthcare the norm.²
Tenovi recently advanced that mission by completing the AgeTech Collaborative™ from AARP Accelerator Program, an 8-week program designed to elevate promising early-stage AgeTech startups.
'Tenovi fully supports the mission of the AgeTech Collaborative™ from AARP to improve lives as people age,' said Nizan Friedman, Ph.D., CEO and co-founder of Tenovi. 'Our platform offers a seamless pathway for companies focused on better health outcomes to scale quickly through our network of over 180 remote patient monitoring partners. This collaboration expands access to innovative point solutions for seniors and reinforces our commitment to delivering comprehensive remote care across all disease states.'
Tenovi's remote monitoring platform enables clinicians to act early when warning signs, such as rising blood pressure may surface. Tenovi's proprietary Cellular Gateway connects over 40 FDA-cleared Bluetooth remote monitoring devices for vital signs, medication adherence, and activity tracking. The plug-and-play platform requires no apps, Wi-Fi, or syncing, and uses a simple red and green LED display system for added measurement adherence. The red light signals it's time for a patient to take a measurement. The green light confirms it was transmitted to their care team.
As Stroke Awareness Month continues, Tenovi remains focused on delivering real-time remote patient and therapeutic monitoring solutions that help prevent complications and improve outcomes for patients most at risk.
About Tenovi
Tenovi is a data aggregation and automation remote monitoring platform connecting medical device manufacturers with remote monitoring programs. It provides over 40 remote patient monitoring and remote therapeutic monitoring (RTM) device point solutions that integrate with its proprietary Cellular Gateway, automating the transfer of patient vitals. Tenovi's API-driven fulfillment and automation services enable seamless deployment of remote patient and therapeutic monitoring programs. To learn more, visit www.tenovi.com or follow on LinkedIn @tenovi, X @tenovihealth.
Sources
2 Hirsch, S. P., & Smith, L. M. (2024). Implementation of remote physiologic monitoring and remote therapeutic monitoring into a primary care practice to improve outcomes for patients with diabetes. Virginia, 2021–2023. Preventing Chronic Disease, 21, E20. Centers for Disease Control and Prevention. https://www.cdc.gov/pcd/issues/2024/23_0267.htm
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
a few seconds ago
- Newsweek
Thousands of Americans Told to Avoid Drive-Thru Lanes
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Thousands of Americans have been told to avoid drive-thru lanes amid concerns over high air pollution levels. The National Weather Service (NWS) has issued air quality alerts in Colorado, Texas, Nevada and Wyoming for Wednesday. The warnings mean ground-level ozone and particulate concentrations are forecast to reach dangerous levels. In some areas, the pollution comes from drifting wildfire smoke. Why It Matters The NWS warned that the general public as well as sensitive groups—children, seniors, and individuals with preexisting respiratory or heart conditions—might experience health effects linked to poor air quality in the affected regions. "Increasing likelihood of respiratory symptoms and breathing discomfort in active children and adults and people with lung disease, such as asthma," the NWS said. "Active children and adults, and people with lung disease, such as asthma, should reduce prolonged or heavy outdoor exertion." People wait in a queue at a drive-thru food distribution event in Austin, Texas, in 2021. People wait in a queue at a drive-thru food distribution event in Austin, Texas, in 2021. Mario Cantu/CSM/ZUMA Wire/Cal Sport Media/AP What To Know In Texas, an Ozone Action Day has been issued for the Houston, Galveston and Brazoria area, and the Dallas-Fort Worth metropolitan area on Wednesday. The Texas Commission on Environmental Quality (TCEQ) said that residents in these areas can reduce ozone pollution by "sharing a ride, walking, riding a bicycle, taking your lunch to work, avoiding drive-thru lanes, conserving energy and keeping your vehicle properly tuned." In Wyoming, an air quality alert for wildfire smoke has been issued until 1 p.m. on Wednesday for portions of the Bighorn Basin, Owl Creek Mountains, Bridger Mountains and Absaroka Mountains. Wildfire smoke across the Bighorn Basin, especially from the Red Canyon Fire, as well as fires in Idaho and Nevada, will continue to spread across the region on Wednesday. In Nevada, an Air Quality Action Day has been forecast for southwest Elko County, including Elko City, for elevated particulate matter. The air pollution is expected to be in the unhealthy for sensitive groups range. Meanwhile in Colorado, an Ozone Action Day Alert has been issued for the Front Range Urban Corridor until 4 p.m. on Wednesday. Hot and stagnant weather will allow ozone levels to reach levels that unhealthy for sensitive groups. "If possible, please help us reduce ozone pollution by limiting driving gas and diesel-powered vehicles until at least 4 p.m.," the Colorado Department of Public Health and Environment said. What People Are Saying The Wyoming Department of Environmental Quality said in a statement: "The Wyoming Department of Health recommends that the elderly, young children, and individuals with respiratory problems avoid excessive physical exertion and minimize outdoor activities during this time. "Wildfire smoke is made up of a variety of pollutants, including particulate matter and ozone, which can cause respiratory health effects. Although these people are most susceptible to health impacts, the Department of Health also advises that everyone should avoid prolonged exposure to poor air quality conditions." Jonathan Grigg, a professor of pediatric respiratory and environmental medicine at Queen Mary University of London, previously told Newsweek that there are "very clear links" between inhaling particles and earlier death from both respiratory and cardiovascular diseases. He added: "There are vulnerable groups and classically they are children because they've got an extra issue to do with their lungs developing, whereas our lungs are not developing as adults." What Happens Next The air quality warnings are currently set to remain in force until Wednesday afternoon in Wyoming and Colorado, and for the whole day in Texas and Nevada. Regular updates regarding air pollution levels are issued on the NWS website and on the Environmental Protection Agency's AirNow interactive map.
Newsweek
a few seconds ago
- Newsweek
'Beware' Mousse-Based Sunscreen, FDA Warns
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some sunscreens may look more appealing than others, the jury is now out on whether certain types do what they say on the bottle. The Food and Drug Administration (FDA) has issued a warning to "beware" sunscreen products that come in mousse form because they might not be effective. The federal agency has sent warning letters to five companies marketing sunscreen products in mousse-style—including brands Supergoop!, Vacation Inc., Kalani Sunwear, Botao Baby and Tizo Skin—and citing efficacy concerns, regulatory violations and packaging risks. Some companies are already pulling products from their U.S. sites, such as Kalani Sunwear. Woman applying sunscreen on man's face outdoors. Woman applying sunscreen on man's face outdoors. JordiThe FDA's letter to Supergoop!, for example, reads in part: "This letter is to advise you that on May 2nd, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website, where your 'Supergoop! PLAY SPF 50 BODY MOUSSE' drug product is available for purchase in the United States without a prescription." It said that based on their labeling—e.g. "Broad Spectrum Sunscreen SPF 50" and "Helps prevent sunburn..."—it is intended for use as an over-the-counter (OTC) sunscreen drug product, but no FDA-approved relevant application is in effect for this. On X, the FDA also warned: "Some mousse sunscreen products resemble whipped cream containers and may put consumers at risk if ingested." Beware of sunscreen products in mousse form because they might not be effective. The FDA issued five warning letters to companies marketing sunscreen products in mousse form: — FDA Drug Information (@FDA_Drug_Info) August 12, 2025 In light of this, Newsweek spoke to dermatologist professor Adam Friedman of the George Washington University about what the FDA warning means for Americans' sunscreen routines and how to choose safe and effective protection. "Sunscreens are OTC drugs, which distinguishes them from a moisturizer or a cosmeceutical. It means the regulation, the expectation in terms of efficacy, how well it works and safety is going to be different," Friedman explained. "But also what it relates to is not just the active ingredient, but the formulation—and that's where the whole mess comes in. "As of right now, under the 'monograph'—the umbrella of what is considered a sunscreen—oils, creams, lotions, gels, butters, pastes, ointments, powders, sprays and sticks fall under the category. Mousses and foams do not." Efficacy and safety are then a separate issue. "A mousse or a foam are aerated, and therefore how they interface with the skin when you rub them on may be very different from a cream or a spray or a stick," said Friedman. "We don't know if, based on that formulation, your UV filters—whether mineral or chemical—are going to behave the same way in the approved formulations. We can't guarantee that these mousse formulation sunscreens will actually work, let alone guarantee their safety." While Friedman said it is "concerning" some brands have not followed the correct process he hopes they were "trying to provide more options to hopefully ensure everyone is using a sun protection product". Smiling woman applying sunscreen on her face while looking in mirror in her bathroom. Smiling woman applying sunscreen on her face while looking in mirror in her bathroom. Ridofranz/Getty Images When deciding how to pick out the best sunscreen, Friedman advises going with the path of least risk. "That's going to be the sunscreens that do follow the monograph," he urged. "I tend to also say, go with the larger brand companies, because they have the size, wherewithal and resources to actually study their products. Not just ensure they meet FDA guidelines, but they'll do clinical studies to look at tolerability, cosmesis [preservation of appearance] and even the effect of these sunscreens on other things. "We use sunscreen not just to protect against skin cancer, but also accelerated skin aging and skin discoloration." Friedman said finding one that's right for you is still important. "Take these tried and true brands and do patch testing to see A) does your skin tolerate it and B) does it rub in well so you're not walking around with a white or purple cast. Samples from the dermatology office are so helpful." He recommends wearing at least an SPF 30 or higher each day. "I tend to say 50, not because there's such a huge delta between 30 and 50—and you will never 100 percent block UV radiation—but because these numbers are based on the FDA approach to measuring efficacy," Friedman said. While it's based on a set concentration of two milligrams of sunscreen per centimeter square of skin, most people don't put that much on. "The higher SPFs are good because it takes into account human error," he added. "With how much people are actually applying, a 70 ends up being a 40 and a 50 ends up being 30. "So in an ideal world: SPF, 30, maybe 50, broad spectrum, water resistant to 80 minutes. Then it's about what plays nice on your skin." Friedman himself wears sunscreen all year round, even in winter. "Every day to exposed areas. Do you brush your teeth every day? Sunscreen is the brushing the teeth of the skin. We brush our teeth to protect the integrity and health of our teeth. Applying sunscreen is the exact same thing." He also emphasized sunscreen is just one protection factor that should be used alongside wearing hats, sunglasses, the right clothing, seeking shade during peak hours and being fully aware. This includes knowing that windows won't block out UVA (while this will less likely cause burning, it can increase the risk of accelerated skin aging because it penetrates deeper). Supergoop! told Newsweek: "At Supergoop! we remain committed to innovation in sun care and the highest standards of product efficacy and safety. The recent communication from the FDA regarding our PLAY SPF 50 Body Mousse is focused on product labeling and has nothing to do with its safety, effectiveness, or formula. We are working closely with the FDA to resolve this matter as we continue to uphold the high standards our consumers expect from us." Vacation Inc told Newsweek: "At Vacation Sunscreen, we take regulatory compliance seriously and appreciate the opportunity to address the U.S. Food and Drug Administration's recent Warning Letter. We have full confidence in the safety, efficacy, and integrity of our product. We are committed to working collaboratively with the FDA to satisfactorily resolve this matter." Kalani Sunwear told Newsweek:"Kalani Sunwear acknowledges receipt of the FDA letter and has voluntarily paused sales in the U.S. while we review the administrative requirements. Importantly, the letter relates to regulatory classification only—not to the safety or efficacy of our SPF 50 mousse. Our formula is manufactured in Sweden, independently tested to EU standards, and uses advanced UV filters that are not yet approved in the U.S. (the FDA has not approved a new UV filter since 1999). We remain fully compliant with European regulations and stand by the quality and effectiveness of our product." Newsweek has also reached out to Botao Baby, Tizo Skin and the FDA for comment. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about sunscreen? Let us know via health@
Business Wire
29 minutes ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
